Cargando…

Chemoresistance is mediated by ovarian cancer leader cells in vitro

BACKGROUND: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimnia, Nazanin, Wilson, Amy L., Green, Emma, Matthews, Amelia, Jobling, Thomas W., Plebanski, Magdalena, Bilandzic, Maree, Stephens, Andrew N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408956/
https://www.ncbi.nlm.nih.gov/pubmed/34470672
http://dx.doi.org/10.1186/s13046-021-02086-3
_version_ 1783746898712068096
author Karimnia, Nazanin
Wilson, Amy L.
Green, Emma
Matthews, Amelia
Jobling, Thomas W.
Plebanski, Magdalena
Bilandzic, Maree
Stephens, Andrew N.
author_facet Karimnia, Nazanin
Wilson, Amy L.
Green, Emma
Matthews, Amelia
Jobling, Thomas W.
Plebanski, Magdalena
Bilandzic, Maree
Stephens, Andrew N.
author_sort Karimnia, Nazanin
collection PubMed
description BACKGROUND: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment. METHODS: CRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined “stemness” profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey’s multiple comparison post hoc. RESULTS: Leader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a “stemness” profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention. CONCLUSIONS: Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-02086-3.
format Online
Article
Text
id pubmed-8408956
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84089562021-09-01 Chemoresistance is mediated by ovarian cancer leader cells in vitro Karimnia, Nazanin Wilson, Amy L. Green, Emma Matthews, Amelia Jobling, Thomas W. Plebanski, Magdalena Bilandzic, Maree Stephens, Andrew N. J Exp Clin Cancer Res Research BACKGROUND: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment. METHODS: CRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined “stemness” profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey’s multiple comparison post hoc. RESULTS: Leader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a “stemness” profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention. CONCLUSIONS: Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-02086-3. BioMed Central 2021-09-01 /pmc/articles/PMC8408956/ /pubmed/34470672 http://dx.doi.org/10.1186/s13046-021-02086-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Karimnia, Nazanin
Wilson, Amy L.
Green, Emma
Matthews, Amelia
Jobling, Thomas W.
Plebanski, Magdalena
Bilandzic, Maree
Stephens, Andrew N.
Chemoresistance is mediated by ovarian cancer leader cells in vitro
title Chemoresistance is mediated by ovarian cancer leader cells in vitro
title_full Chemoresistance is mediated by ovarian cancer leader cells in vitro
title_fullStr Chemoresistance is mediated by ovarian cancer leader cells in vitro
title_full_unstemmed Chemoresistance is mediated by ovarian cancer leader cells in vitro
title_short Chemoresistance is mediated by ovarian cancer leader cells in vitro
title_sort chemoresistance is mediated by ovarian cancer leader cells in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408956/
https://www.ncbi.nlm.nih.gov/pubmed/34470672
http://dx.doi.org/10.1186/s13046-021-02086-3
work_keys_str_mv AT karimnianazanin chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT wilsonamyl chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT greenemma chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT matthewsamelia chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT joblingthomasw chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT plebanskimagdalena chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT bilandzicmaree chemoresistanceismediatedbyovariancancerleadercellsinvitro
AT stephensandrewn chemoresistanceismediatedbyovariancancerleadercellsinvitro